-
Taxonomy & unit
-
us-gaap: shares
-
Description
-
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
-
Summary
-
Revance Therapeutics, Inc. quarterly/annual Weighted Average Number of Shares Outstanding, Diluted history and growth rate from Q1 2013 to Q3 2024.
- Revance Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending September 30, 2024 was 104M shares, a 20.3% increase year-over-year.
- Revance Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 84.6M shares, a 16.3% increase from 2022.
- Revance Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 72.7M shares, a 7.71% increase from 2021.
- Revance Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2021 was 67.5M shares, a 16.4% increase from 2020.
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Growth (%)